Synergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 1208-1214

  Zapała, Łukasz ^a   Wolny, Rafał ^a   Wachowska, Małgorzata ^a   Jakóbisiak, Marek ^a   Lasek, Witold ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cancer vaccine; Dendritic cell; Interleukin 12; Melanoma

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; JAWSII DENDRITIC CELL VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LYSATE; CELL STIMULATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DENDRITIC CELL; DISEASE CONTROL; DRUG POTENTIATION; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; VACCINATION;

ANIMALS; ANTIGENS, CD; CANCER VACCINES; CELL EXTRACTS; CELL LINE; DENDRITIC CELLS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-12; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PHAGOCYTOSIS; POLY I-C;

EID: 84872788695     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2193     Document Type: Article

References (31)

1. Ueno H, Klechevsky E, Morita R, et al: Dendritic cell subsets in health and disease. Immunol Rev 219: 118-142, 2007. (Pubitemid 47393528)
2. Palucka K, Ueno H, Roberts L, Fay J and Banchereau J: Dendritic cell subsets as vectors and targets for improved cancer therapy. Curr Top Microbiol Immunol 344: 173-192, 2012.
3. Gilboa E: DC-based cancer vaccines. J Clin Invest 117: 1195-1203, 2007. (Pubitemid 46718404)
4. Pajtasz-Piasecka E and Indrova M: Dendritic cell-based vaccines for the therapy of experimental tumors. Immunotherapy 2: 257-268, 2010.
5. Palucka K, Ueno H and Banchereau J: Recent developments in cancer vaccines. J Immunol 186: 1325-1331, 2011.
6. Rossowska J, Pajtasz-Piasecka E, Szyda A, Krawczenko A, Zietara N and Dus D: Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo. Oncol Rep 21: 1539-1549, 2009.
7. Vegh Z and Mazumder A: Generation of tumor cell lysate-loaded dendritic cells preprogrammed for IL-12 production and augmented T cell response. Cancer Immunol Immunother 52: 67-79, 2003. (Pubitemid 36337614)
8. Tatsumi T, Takehara T, Kanto T, et al: Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 61: 7563-7567, 2001. (Pubitemid 32995049)
9. Fallarino F, Uyttenhove C, Boon T and Gajewski TF: Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int J Cancer 80: 324-333, 1999. (Pubitemid 29001740)
10. Gately MK, Warrier RR, Honasoge S, et al: Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 6: 157-167, 1994. (Pubitemid 24040344)
11. McKnight AJ, Zimmer GJ, Fogelman I, Wolf SF and Abbas AK: Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol 152: 2172-2179, 1994.
12. Brunda MJ, Luistro L, Rumennik L, et al: Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol 38 (Suppl): S16-S21, 1996.
13. Nastala CL, Edington HD, McKinney TG, et al: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153: 1697-1706, 1994. (Pubitemid 24251114)
14. Pajtasz-Piasecka E, Rossowska J, Szyda A, Krawczenko A and Dus D: Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes. Oncol Rep 17: 1249-1257, 2007.
15. Xu Y, Darcy PK and Kershaw MH: Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2. Cancer Gene Ther 14: 773-780, 2007. (Pubitemid 47262758)
16. Zapala L, Drela N, Bil J, Nowis D, Basak GW and Lasek W: Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application. Oncol Rep 25: 831-840, 2011.
17. Basak GW, Zapala L, Wysocki PJ, Mackiewicz A, Jakobisiak M and Lasek W: Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model. Oncol Rep 19: 1173-1179, 2008.
18. Switaj T, Jalili A, Jakubowska AB, et al: CpG immunostimu-latory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin Cancer Res 10: 4165-4175, 2004. (Pubitemid 38812497)
19. Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P and Nencioni A: Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev 60: 173-183, 2008. (Pubitemid 350236398)
20. Palucka K and Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12: 265-277, 2012.
21. Haase C, Michelsen BK and Jorgensen TN: CD40 is necessary for activation of naive T cells by a dendritic cell line in vivo but not in vitro. Scand J Immunol 59: 237-245, 2004. (Pubitemid 38429289)
22. Jorgensen TN, Haase C and Michelsen BK: Treatment of an immortalized APC cell line with both cytokines and LPS ensures effective T-cell activation in vitro. Scand J Immunol 56: 492-503, 2002. (Pubitemid 35373686)
23. Peterson AC, Harlin H and Gajewski TF: Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21: 2342-2348, 2003. (Pubitemid 46628465)
24. Wehner R, Dietze K, Bachmann M and Schmitz M: The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun 3: 258-263, 2011.
25. Manetti R, Parronchi P, Giudizi MG, et al: Natural killer cell stimulatory factor [interleukin 12 (IL-12)] induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177: 1199-1204, 1993. (Pubitemid 23097410)
26. -/- mice and involves NK cells. J Mol Med 88: 775-784, 2010.
27. Airoldi I, Di Carlo E, Cocco C, et al: Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci USA 104: 3996-4001, 2007. (Pubitemid 47181567)
28. Hill HC, Conway TF Jr, Sabel MS, et al: Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 62: 7254-7263, 2002. (Pubitemid 36025247)
29. Kozar K, Kaminski R, Switaj T, et al: Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin Cancer Res 9: 3124-3133, 2003. (Pubitemid 36993275)
30. Grohmann U, Bianchi R, Ayroldi E, et al: A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J Immunol 158: 3593-3602, 1997. (Pubitemid 127488711)
31. Kelleher P and Knight SC: IL-12 increases CD80 expression and the stimulatory capacity of bone marrow-derived dendritic cells. Int Immunol 10: 749-755, 1998. (Pubitemid 28279477)